Hovione plans to expand its new capacity and capabilities in Portugal, Ireland, and New Jersey with an investment of US$170 million.
This expansion of industrial facilities across the world will support its ambitious growth objectivesto meet customer needs.
The expansion will support the growing demand for pharma custom development and manufacturing service business followed by integrated and differentiated services in drug substance manufacturing, particle engineering and drug product manufacturing.
Expansion of Units in New Jersey, Ireland and Portugal
In USA, the new state-of-the-art2900m2 campus will be located adjacent to current facility in East Windsor, New Jersey. The new building will additional commercial spray drying capacity online by 2023.
The expansion will allow both the current and new customers of US-based manufacturing through their development cycles all the way to commercial.
In Ireland, the facility at will be upgraded to increase the production of Highly Potent Active Pharmaceutical Ingredients (HPAPI). In addition, with the addition of unique technologiesthe site supports huge customer projects finding a new home by connecting to the existing infrastructure and equipment.
In Portugal, the facility is designed due to the increase in chemical synthesis capacity for High Potency Active Pharmaceutical Ingredients (HPAPI).
The new expansion will creat more than 300 new jobs globally.